178 related articles for article (PubMed ID: 38665913)
21. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
22. Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade.
He M; Chen ZF; Zhang L; Gao X; Chong X; Li HS; Shen L; Ji J; Zhang X; Dong B; Li ZY; Lei T
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349127
[TBL] [Abstract][Full Text] [Related]
23. Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy.
Wang Z; Zhang L; Wang J; Wang Y; Dong Q; Piao H; Wang Q; Zhang J
J Immunol Res; 2020; 2020():6813176. PubMed ID: 32832571
[TBL] [Abstract][Full Text] [Related]
24. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
25. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery.
Bi S; Jiang Y; Guan G; Sun X; Wang X; Zhang L; Jing X
Ann Surg Oncol; 2024 May; 31(5):2913-2924. PubMed ID: 38319516
[TBL] [Abstract][Full Text] [Related]
27. U-shaped relationship between subcutaneous adipose tissue index and mortality in liver cirrhosis.
Zhu M; Li H; Yin Y; Ding M; Philips CA; Romeiro FG; Qi X
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):508-516. PubMed ID: 36577511
[TBL] [Abstract][Full Text] [Related]
28. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial.
Hacker UT; Hasenclever D; Linder N; Stocker G; Chung HC; Kang YK; Moehler M; Busse H; Lordick F
J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):135-144. PubMed ID: 31464089
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
31. Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy.
Kuang T; Zhang L; Qiu Z; Zhang Y; Wang W
Front Immunol; 2023; 14():1261202. PubMed ID: 38077332
[TBL] [Abstract][Full Text] [Related]
32. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.
Randon G; Aoki Y; Cohen R; Provenzano L; Nasca V; Klempner SJ; Maron SB; Cerantola R; Chao J; Fornaro L; Ferrari Bravo W; Ghelardi F; Ambrosini M; Manca P; Salati M; Kawazoe A; Zhu V; Cowzer D; Genovesi V; Lonardi S; Shitara K; André T; Pietrantonio F
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277193
[TBL] [Abstract][Full Text] [Related]
33. Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
Franzoi MA; Vandeputte C; Eiger D; Caparica R; Brandão M; De Angelis C; Hendlisz A; Awada A; Piccart M; de Azambuja E
Breast Cancer Res Treat; 2020 May; 181(1):199-209. PubMed ID: 32246377
[TBL] [Abstract][Full Text] [Related]
34. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
Deng G; Zhu D; Du Z; Xue Y; Song H; Li Y
Cancer Med; 2024 Mar; 13(6):e7110. PubMed ID: 38506237
[TBL] [Abstract][Full Text] [Related]
35. Serum creatinine/cystatin C ratio as a prognostic indicator for patients with colorectal cancer.
Gao S; Xie H; Wei L; Liu M; Liang Y; Wang Q; Tang S; Gan J
Front Oncol; 2023; 13():1155520. PubMed ID: 37409249
[TBL] [Abstract][Full Text] [Related]
36. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
[TBL] [Abstract][Full Text] [Related]
38. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of prognostic nutritional index in advanced cancer receiving PD-1/L1 inhibitors: A meta-analysis.
Li P; Lai Y; Tian L; Zhou Q
Cancer Med; 2022 Aug; 11(16):3048-3056. PubMed ID: 35297197
[TBL] [Abstract][Full Text] [Related]
40. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
Naik GS; Waikar SS; Johnson AEW; Buchbinder EI; Haq R; Hodi FS; Schoenfeld JD; Ott PA
J Immunother Cancer; 2019 Mar; 7(1):89. PubMed ID: 30922394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
